Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FHTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $103.14M
- P/E (TTM)
- 19.11
- EPS (TTM)
- $0.09
- Dividend yield
- None
- 52-week range
- 1.66 – 7.61
- Day range
- 1.66 – 1.80
- Volume / Avg
- 919.93K / 843.73K
- Beta
- —
- Shares outstanding
- 59.96M
52-week range
FHTX stock today
Foghorn Therapeutics (FHTX) closed at $1.72 on Nov 20, down 3.37% (-$0.06), versus the S&P 500's 3.70% decline. At this level, FHTX sits near the bottom of its 52-week range of $1.66 to $7.61: 77.4% below the high, set on Aug 20, 2026 and 3.6% above the low. FHTX is down 68.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.8%.
Foghorn Therapeutics trades at 19.1x its trailing twelve-month earnings per share of $0.09.
Summary generated from market data by MetaCap's automated system. Methodology
About Foghorn Therapeutics
Company profileFoghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Adrian H. B. Gottschalk
- Headquarters
- Watertown, MA
- Employees
- 106
- IPO year
- 2020
- Website
- foghorntx.com
Financial highlights
Full financialsIn fiscal 2025, Foghorn Therapeutics generated $30.9 million in revenue, up 36.8% from fiscal 2024. Foghorn Therapeutics reported a net loss of $74.3 million, compared with a loss of $86.6 million a year earlier. Operating margin was -279.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $30.91M | $22.60M | $34.16M | $19.23M | $1.32M |
| Growth | +36.75% | -33.83% | +77.63% | +1357.77% | +206.74% |
| Net income | $-74.28M | $-86.62M | $-98.43M | $-108.88M | $-101.32M |
| EPS (diluted) | $-1.18 | $-1.58 | $-2.34 | $-2.62 | $-2.73 |
Analyst forecast
ForecastConsensus (10 analysts)
buy
Avg. price target
$4.17+142.44%
- Strong buy 0
- Buy 5
- Hold 5
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $0.80 vs $-0.23
- Surprise
- +447.83%
FHTX news
All FHTX news- Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate UpdateGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXPR Newswire
Foghorn Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GNLXGenelux Corporation | 2.17 | -4.82% | $103.36M | vs FHTX |
| ORGOOrganogenesis Holdings Inc. Class A | 0.7716 | -2.23% | $100.16M | vs FHTX |
| NERVMinerva Neurosciences Inc | 2.00 | -5.66% | $99.67M | vs FHTX |
| AKBAAkebia Therapeutics Inc. | 0.3855 | -8.71% | $107.04M | vs FHTX |
| CNTNCanton Strategic Holdings Inc. | 1.21 | -1.63% | $98.78M | vs FHTX |
| UNCYUnicycive Therapeutics Inc. | 3.35 | -5.10% | $97.77M | vs FHTX |
| BGMBGM Group Ltd. Class A | 8.13 | 0.00% | $108.57M | vs FHTX |
| SPRBSpruce Biosciences Inc. | 38.00 | -6.15% | $109.21M | vs FHTX |
Indexes, lists and sector
Foghorn Therapeutics stock FAQ
What is Foghorn Therapeutics's stock price today?
FHTX last traded at $1.72 as of Nov 20, 4:00 PM EST, down 3.37% on the day. Prices are delayed at least 15 minutes.
What is FHTX's P/E ratio?
FHTX trades at a trailing P/E ratio of 19.11.
Who is Foghorn Therapeutics's CEO?
Mr. Adrian H. B. Gottschalk is the chief executive officer of Foghorn Therapeutics Inc., which has about 106 employees.
What is the FHTX 52-week high?
The 52-week high for FHTX is $7.61 and the 52-week low is $1.66. The stock is currently 77.4% below its high.